|
(MoneyNewsWire.Net, February 18, 2016 ) Description-
Summary
GlobalDatas new report, "France Genetic Testing Market Outlook to 2021", provides key market data on the France Genetic Testing market. The report provides value, in millions of US dollars within market segments - Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests.
The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with industry experts to validate the market size, company share and distribution share data and analysis.
Scope
- Genetic Testing market includes Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests.
- Annualized market revenues (USD million) data for each of the market categories. Data is provided from 2007 to 2014 and forecast to 2021.
- 2014 company shares and distribution shares data for Genetic Testing market.
- Global corporate-level profiles of key companies operating within the France Genetic Testing market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Danaher Corporation, Abbott Laboratories, Hologic, Inc., Cepheid, Bio-Rad Laboratories, Inc., Qiagen N.V., Transgenomic, Inc. and PerkinElmer, Inc.
Reasons to buy
- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and whats the most preferred mode of product distribution - Identify, understand and capitalize.
Table of Contents
5 Genetic Testing Market Pipeline Products 17
6 Financial Deals Landscape 21
6.1 Asset Transactions 21
6.1.1 Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation for USD14.5 Million 21
6.2 Merger 23
6.2.1 Biosynex to Merge with Prodiag 23
6.3 Partnerships 24
6.3.1 KromaTiD Enters into Distribution Agreement with Tebu-bio 24
6.3.2 Tataa Biocenter Enters into Licensing Agreement with Inserm for ValidPrime Technology 25
7 Recent Developments 26
7.1 Financial Announcements 26
7.1.1 Apr 01, 2015: The Medicines Company Settles Angiomax (Bivalirudin) Patent Litigation With Sun 26
7.1.2 Mar 26, 2015: Diaxonhit Announces 2014 Annual Results 28
7.1.3 Jan 26, 2015: DIAXONHIT - 2014 Consolidated Income 30
7.2 Other Significant Developments 31
7.2.1 Feb 05, 2015: IntegraGen Announces Distribution Agreement for Autism Risk Assessment Test 31
8 Appendix 32
8.1 Research Methodology 33
8.1.1 Coverage 33
8.1.2 Secondary Research 33
8.1.3 Primary Research 33
8.1.4 Company Share Analysis 34
8.1.5 Distribution Share Analysis 34
8.2 GlobalData Consulting 34
8.3 Contact Us 34
8.4 Disclaimer 35
Request_a_Sample-http://www.researchmoz.us/enquiry.php?type=S&repid=483289
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074,
USA-Canada Toll Free: 866-997-4948,
Email: sales@researchmoz.us,
Website: http://www.researchmoz.us
Researchmoz Global Pvt.Ltd
Researchmoz, Mr. Nachiket Ghumare
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
|
